Abeona Therapeutics (ABEO)
Commercializes ZEVASKYN for RDEB wounds through qualified treatment centers.
Something off on this page? Send us feedback.
Sells ZEVASKYN, an autologous cell-based gene therapy for RDEB wounds, through a qualified-treatment-center model. Operations are centered in Cleveland, where Abeona runs its own cGMP manufacturing facility and carries FDA-required long-term safety follow-up for treated patients.
Develops and sells ZEVASKYN, also known as prademagene zamikeracel, for wounds in adults and children with recessive dystrophic epidermolysis bullosa. The company reports a single segment and has added ABO-701 as an early pipeline asset after deprioritizing ophthalmology programs.
Commercial execution runs through qualified treatment centers and an internal Cleveland cGMP facility, the Elisa Linton Center. That setup gives the launch a narrow operating model: patient biopsy, manufacturing, and treatment-site readiness matter as much as conventional drug distribution.
Regulatory obligations remain part of the business model. FDA approval carries long-term postmarketing safety follow-up for treated patients, and current operations are shaped by ZEVASKYN commercialization rather than a broad mature portfolio.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 17, 2026 | Roth Capital | Initiate | Rating: —Target: — | Target: $17 |
| Aug 14, 2026 | Industrial Alliance Securities | Target | Target: — | Target: $15 |
| Aug 14, 2026 | Oppenheimer | Reiterate | Rating: —Target: $16 | Target: $21 |
| Mar 17, 2026 | Stifel Nicolaus | Target | Target: $20 | Target: $17 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $146.8M · Total debt $19.9M · Total assets $179.5M · Shareholders' equity $128.1M
- Revenue
- $11.4M
- Operating income
- −$13.7M
- Net income
- −$20.2M
No dividends on record.
| Insiders | 11.68% | 6.68M shares | |
|---|---|---|---|
| 14 holders · as of Sep 1, 2026 | |||
| Strategic holders | 14.93% | 8.54M shares | |
| 4 holders · as of Sep 30, 2025 | |||
| Other | 73.39% | 41.97M shares | |
| remainder | |||
57.18M company shares as of Sep 23, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Nantahala Capital Management, LLCInstitution | 10.10% | 5.78M | filed May 15, 2026 |
Nantahala Capital Partners Limited PartnershipInstitution | 5.83% | 3.33M | filed May 15, 2026 |
Orin HirschmanInsider | 5.42% | 3.10M | filed Apr 28, 2026 |
Funicular Funds, LPInstitution | 5.26% | 3.01M | filed Apr 6, 2026 |
BlackRock, Inc.Strategic | 5.16% | 2.95M | filed Jul 17, 2025 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 1, 2026 | Mark Alvino | director | −15,000 | $5.86 |
| Jul 21, 2026 | Joseph Walter Vazzano | officer: Chief Financial Officer | −1,478 | $6.53 |
| Jul 9, 2026 | Madhav Vasanthavada | officer: Chief Commercial Officer | −12,606 | $6.96 |
| Jul 9, 2026 | Brendan M. O'Malley | officer: SVP, Chief Legal Officer | −12,050 | $6.96 |
| Jul 9, 2026 | Vishwas Seshadri | director, officer: Chief Executive Officer | −67,971 | $6.96 |
- Krystal Biotech
Direct DEB wound gene-therapy rival with VYJUVEK
- Vericel
Autologous cell-therapy peer in skin replacement and burns
- Rocket Pharmaceuticals
Rare pediatric ex vivo gene-therapy peer with KRESLADI
- Sarepta Therapeutics
Scaled rare-disease gene-therapy operator with ELEVIDYS
- Vertex Pharmaceuticals
Large cell/gene therapy commercial peer with CASGEVY
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Abeona Therapeutics | $5.57 | −4.27% | $331.7M | — | — | 13.0 | +2,745.0% |
| Krystal Biotech | $340.20 | −3.04% | $10.34B | 44.0 | 40.0 | 23.5 | +24.1% |
| Vericel | $38.34 | −4.67% | $2.06B | 86.0 | 57.3 | 6.7 | +22.5% |
| Rocket Pharmaceuticals | $3.12 | −7.01% | $365.8M | — | — | — | — |
| Sarepta Therapeutics | $19.15 | −7.98% | $2.20B | — | 33.3 | 1.1 | −34.3% |
| Vertex Pharmaceuticals | $511.95 | −0.59% | $130.71B | 30.0 | 26.6 | 10.4 | +12.5% |
| Median | 44.0 | 36.7 | 8.5 | +17.5% |